NDAORALCAPSULE, EXTENDED RELEASE
Approved
Jul 1982
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
NORPACE CR (disopyramide phosphate) by Pfizer is mechanisms of action norpace (disopyramide phosphate) is a type 1 antiarrhythmic drug (i. Approved for documented ventricular arrhythmias, such, that and 1 more indications. First approved in 1982.
Drug data last refreshed 10h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NORPACE CR is a Type IA antiarrhythmic agent (disopyramide phosphate) administered orally as an extended-release capsule for treating documented ventricular arrhythmias. It works by decreasing diastolic depolarization rates, slowing conduction velocity, and increasing action potential duration in cardiac tissue without affecting adrenergic receptors.
$0.813MPart D
LOE ApproachingDeclining
Product is in LOE-approaching phase with minimal Medicare Part D utilization (~$813K annual spending), indicating a mature, declining franchise with limited commercial growth opportunities.
Mechanism of Action
Mechanisms of Action Norpace (disopyramide phosphate) is a Type 1 antiarrhythmic drug (i.e., similar to procainamide and quinidine). In animal studies Norpace decreases the rate of diastolic depolarization (phase 4) in cells with augmented automaticity, decreases the upstroke velocity (phase 0) and…
Indications (4)
Worked on NORPACE CR at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.